Analysis of the Kinetics and Effects of Vemurafenib + Cobimetinib on Intratumoral and Host Immunity in Patients With Advanced BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2017
At a glance
- Drugs Vemurafenib (Primary) ; Cobimetinib
- Indications Malignant melanoma
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 02 Mar 2017 Status changed from recruiting to discontinued.
- 08 Dec 2015 Cobimetinib has been added to treatment, Official title changed as reported by ClinicalTrials.gov.